These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 23886514

  • 1. Acute neural effects of selective serotonin reuptake inhibitors versus noradrenaline reuptake inhibitors on emotion processing: Implications for differential treatment efficacy.
    Outhred T, Hawkshead BE, Wager TD, Das P, Malhi GS, Kemp AH.
    Neurosci Biobehav Rev; 2013 Sep; 37(8):1786-800. PubMed ID: 23886514
    [Abstract] [Full Text] [Related]

  • 2. Noradrenaline and serotonin reuptake inhibition as clinical principles: a review of antidepressant efficacy.
    Humble M.
    Acta Psychiatr Scand Suppl; 2000 Sep; 402():28-36. PubMed ID: 10901156
    [Abstract] [Full Text] [Related]

  • 3. Differential modulation of emotion processing brain regions by noradrenergic and serotonergic antidepressants.
    Brühl AB, Jäncke L, Herwig U.
    Psychopharmacology (Berl); 2011 Aug; 216(3):389-99. PubMed ID: 21359508
    [Abstract] [Full Text] [Related]

  • 4. Antidepressant drugs: does it matter if they inhibit the reuptake of noradrenaline or serotonin?
    Eriksson E.
    Acta Psychiatr Scand Suppl; 2000 Aug; 402():12-7. PubMed ID: 10901154
    [Abstract] [Full Text] [Related]

  • 5. Depletion of serotonin and catecholamines block the acute behavioral response to different classes of antidepressant drugs in the mouse tail suspension test.
    O'Leary OF, Bechtholt AJ, Crowley JJ, Hill TE, Page ME, Lucki I.
    Psychopharmacology (Berl); 2007 Jun; 192(3):357-71. PubMed ID: 17318507
    [Abstract] [Full Text] [Related]

  • 6. Distinguishing roles for norepinephrine and serotonin in the behavioral effects of antidepressant drugs.
    Lucki I, O'Leary OF.
    J Clin Psychiatry; 2004 Jun; 65 Suppl 4():11-24. PubMed ID: 15046537
    [Abstract] [Full Text] [Related]

  • 7. Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment.
    McCabe C, Mishor Z, Cowen PJ, Harmer CJ.
    Biol Psychiatry; 2010 Mar 01; 67(5):439-45. PubMed ID: 20034615
    [Abstract] [Full Text] [Related]

  • 8. Pharmacological principles of antidepressant efficacy.
    Schatzberg AF.
    Hum Psychopharmacol; 2002 Jun 01; 17 Suppl 1():S17-22. PubMed ID: 12404665
    [Abstract] [Full Text] [Related]

  • 9. Norepinephrine involvement in antidepressant action.
    Frazer A.
    J Clin Psychiatry; 2000 Jun 01; 61 Suppl 10():25-30. PubMed ID: 10910014
    [Abstract] [Full Text] [Related]

  • 10. [Consequences of the monoaminergic systems cross-talk in the antidepressant activity].
    Tritschler L, Gaillard R, Gardier AM, David DJ, Guilloux JP.
    Encephale; 2018 Jun 01; 44(3):264-273. PubMed ID: 29801770
    [Abstract] [Full Text] [Related]

  • 11. The impact of 5-HTTLPR on acute serotonin transporter blockade by escitalopram on emotion processing: preliminary findings from a randomised, crossover fMRI study.
    Outhred T, Das P, Dobson-Stone C, Felmingham KL, Bryant RA, Nathan PJ, Malhi GS, Kemp AH.
    Aust N Z J Psychiatry; 2014 Dec 01; 48(12):1115-25. PubMed ID: 24810870
    [Abstract] [Full Text] [Related]

  • 12. Regulation of the norepinephrine transporter by chronic administration of antidepressants.
    Benmansour S, Altamirano AV, Jones DJ, Sanchez TA, Gould GG, Pardon MC, Morilak DA, Frazer A.
    Biol Psychiatry; 2004 Feb 01; 55(3):313-6. PubMed ID: 14744474
    [Abstract] [Full Text] [Related]

  • 13. Serotonergic and noradrenergic reuptake inhibitors: prediction of clinical effects from in vitro potencies.
    Frazer A.
    J Clin Psychiatry; 2001 Feb 01; 62 Suppl 12():16-23. PubMed ID: 11430614
    [Abstract] [Full Text] [Related]

  • 14. Augmentation strategies with serotonergic-noradrenergic combinations.
    Nelson JC.
    J Clin Psychiatry; 1998 Feb 01; 59 Suppl 5():65-8; discussion 69. PubMed ID: 9635550
    [Abstract] [Full Text] [Related]

  • 15. Milnacipran and selective serotonin reuptake inhibitors in major depression.
    Lopez-Ibor J, Guelfi JD, Pletan Y, Tournoux A, Prost JF.
    Int Clin Psychopharmacol; 1996 Sep 01; 11 Suppl 4():41-6. PubMed ID: 8923126
    [Abstract] [Full Text] [Related]

  • 16. The dual-action hypothesis: does pharmacology matter?
    Shelton RC.
    J Clin Psychiatry; 2004 Sep 01; 65 Suppl 17():5-10. PubMed ID: 15600376
    [Abstract] [Full Text] [Related]

  • 17. Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. Meta-regression analysis.
    Freemantle N, Anderson IM, Young P.
    Br J Psychiatry; 2000 Oct 01; 177():292-302. PubMed ID: 11116769
    [Abstract] [Full Text] [Related]

  • 18. Impact of acute administration of escitalopram on the processing of emotional and neutral images: a randomized crossover fMRI study of healthy women.
    Outhred T, Das P, Felmingham KL, Bryant RA, Nathan PJ, Malhi GS, Kemp AH.
    J Psychiatry Neurosci; 2014 Jul 01; 39(4):267-75. PubMed ID: 24690370
    [Abstract] [Full Text] [Related]

  • 19. Differential effects of the 5-HT2 receptor antagonist on the anti-immobility effects of noradrenaline and serotonin reuptake inhibitors in the forced swimming test.
    Yamada J, Sugimoto Y.
    Brain Res; 2002 Dec 20; 958(1):161-5. PubMed ID: 12468041
    [Abstract] [Full Text] [Related]

  • 20. Effects of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalon and frontal cortex.
    Felton TM, Kang TB, Hjorth S, Auerbach SB.
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Mar 20; 367(3):297-305. PubMed ID: 12644903
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.